Back to Journals » ImmunoTargets and Therapy

ImmunoTargets and Therapy


Journal Articles:

- 73 records -

Immunological targets for cancer therapy: new recognition

Shurin MR

ImmunoTargets and Therapy 2018, 7:83-85

Published Date: 21 November 2018

Alteration of gene expression profile in CD3+ T-cells after downregulating MALT1

Wang X, Lu S, Xiao Y, Xu L, Zhou L, Hu JY, Li B, Zeng C, Li Y

ImmunoTargets and Therapy 2018, 7:77-81

Published Date: 20 November 2018

Review of checkpoint immunotherapy for the management of non-small cell lung cancer

Raju S, Joseph R, Sehgal S

ImmunoTargets and Therapy 2018, 7:63-75

Published Date: 31 July 2018

Multiple effects of CD40–CD40L axis in immunity against infection and cancer

Ara A, Ahmed KA, Xiang J

ImmunoTargets and Therapy 2018, 7:55-61

Published Date: 28 June 2018

Melanoma treatment in review

Domingues B, Lopes JM, Soares P, Pópulo H

ImmunoTargets and Therapy 2018, 7:35-49

Published Date: 7 June 2018

Oncogenes in immune cells as potential therapeutic targets

Zakiryanova GK, Wheeler S, Shurin MR

ImmunoTargets and Therapy 2018, 7:21-28

Published Date: 11 April 2018

Immunotherapy in Merkel cell carcinoma: role of Avelumab

Palla AR, Doll D

ImmunoTargets and Therapy 2018, 7:15-19

Published Date: 2 March 2018

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer

Belzile O, Huang X, Gong J, Carlson J, Schroit AJ, Brekken RA, Freimark BD

ImmunoTargets and Therapy 2018, 7:1-14

Published Date: 23 January 2018

The current status of immunobased therapies for metastatic renal-cell carcinoma

Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS

ImmunoTargets and Therapy 2017, 6:83-93

Published Date: 5 December 2017

CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy

Xu A, Freywald A, Xie Y, Li Z, Xiang J

ImmunoTargets and Therapy 2017, 6:39-49

Published Date: 15 June 2017

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer

Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, Lam R, Drake CG

ImmunoTargets and Therapy 2017, 6:11-16

Published Date: 20 March 2017

First-line treatment of metastatic melanoma: role of nivolumab

Force J, Salama AK

ImmunoTargets and Therapy 2017, 6:1-10

Published Date: 13 February 2017

Prion diseases: immunotargets and therapy

Burchell JT, Panegyres PK

ImmunoTargets and Therapy 2016, 5:57-68

Published Date: 16 June 2016

The role of adipokines in chronic inflammation

Mancuso P

ImmunoTargets and Therapy 2016, 5:47-56

Published Date: 23 May 2016

Immunotherapy for tuberculosis: future prospects

Abate G, Hoft DF

ImmunoTargets and Therapy 2016, 5:37-45

Published Date: 20 April 2016

Current and emerging treatment options in the management of lupus

Jordan N, D’Cruz D

ImmunoTargets and Therapy 2016, 5:9-20

Published Date: 2 March 2016

The role of regulatory T cells in cancer immunology

Whiteside TL

ImmunoTargets and Therapy 2015, 4:159-171

Published Date: 5 August 2015

The hygiene hypothesis: current perspectives and future therapies

Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB

ImmunoTargets and Therapy 2015, 4:143-157

Published Date: 27 July 2015

Novel perspectives on non-canonical inflammasome activation

Diamond CE, Khameneh HJ, Brough D, Mortellaro A

ImmunoTargets and Therapy 2015, 4:131-141

Published Date: 24 July 2015

Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy

Altabas V, Zjačić-Rotkvić V

ImmunoTargets and Therapy 2015, 4:123-130

Published Date: 9 July 2015

CD28 co-stimulation in T-cell homeostasis: a recent perspective

Beyersdorf N, Kerkau T, Hünig T

ImmunoTargets and Therapy 2015, 4:111-122

Published Date: 28 May 2015

Emerging roles for HMGB1 protein in immunity, inflammation, and cancer

Martinotti S, Patrone M, Ranzato E

ImmunoTargets and Therapy 2015, 4:101-109

Published Date: 26 May 2015

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE

ImmunoTargets and Therapy 2015, 4:91-100

Published Date: 15 May 2015

Update on use of aldesleukin for treatment of high-risk metastatic melanoma

Amaria RN, Reuben A, Cooper ZA, Wargo JA

ImmunoTargets and Therapy 2015, 4:79-89

Published Date: 7 April 2015

Emerging role of Natural killer cells in oncolytic virotherapy

Bhat R, Rommelaere J

ImmunoTargets and Therapy 2015, 4:65-77

Published Date: 31 March 2015

Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy

Perna SK, Huye LE, Savoldo B

ImmunoTargets and Therapy 2015, 4:55-63

Published Date: 19 March 2015

Development of antibody-based c-Met inhibitors for targeted cancer therapy

Lee D, Sung ES, Ahn JH, An S, Huh J, You WK

ImmunoTargets and Therapy 2015, 4:35-44

Published Date: 9 February 2015

Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?

Kohyama K, Matsumoto Y

ImmunoTargets and Therapy 2015, 4:27-34

Published Date: 8 January 2015

The role of autophagy in microbial infection and immunity

Desai M, Fang R, Sun J

ImmunoTargets and Therapy 2015, 4:13-26

Published Date: 6 January 2015

Antigen-based immunotherapy for autoimmune disease: current status

Hirsch DL, Ponda P

ImmunoTargets and Therapy 2015, 4:1-11

Published Date: 16 December 2014

Therapeutic cancer vaccines and combination immunotherapies involving vaccination

Nguyen T, Urban J, Kalinski P

ImmunoTargets and Therapy 2014, 3:135-150

Published Date: 6 October 2014

Nanocarrier-based immunotherapy in cancer management and research

Singh MS, Bhaskar S

ImmunoTargets and Therapy 2014, 3:121-134

Published Date: 26 June 2014

Hairy cell leukemia – immunotargets and therapies

Basheer F, Bloxham DM, Scott MA, Follows GA

ImmunoTargets and Therapy 2014, 3:107-120

Published Date: 24 June 2014

Clinical potential of apremilast in the treatment of psoriatic arthritis

Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A

ImmunoTargets and Therapy 2014, 3:91-96

Published Date: 9 June 2014

Emerging options for the treatment of melanoma – focus on ipilimumab

Roddie C, Peggs KS

ImmunoTargets and Therapy 2014, 3:67-78

Published Date: 17 March 2014

Interleukin-17 and type 17 helper T cells in cancer management and research

Llosa NJ, Geis AL, Thiele Orberg E, Housseau F

ImmunoTargets and Therapy 2014, 3:39-54

Published Date: 10 March 2014

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

Arnason JE, Brown JR

ImmunoTargets and Therapy 2014, 3:29-38

Published Date: 24 January 2014

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?

Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R

ImmunoTargets and Therapy 2014, 3:19-28

Published Date: 27 December 2013

Implications of chemokine receptors and inflammatory lipids in cancer

Rolin J, Maghazachi AA

ImmunoTargets and Therapy 2014, 3:9-18

Published Date: 24 December 2013

Therapeutic vaccines in non-small cell lung cancer

Socola F, Scherfenberg N, Raez LE

ImmunoTargets and Therapy 2013, 2:115-124

Published Date: 19 September 2013

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease

Lambracht-Washington D, Rosenberg RN

ImmunoTargets and Therapy 2013, 2:105-114

Published Date: 12 August 2013

Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities

Graves A, Hessamodini H, Wong G,Lim WH

ImmunoTargets and Therapy 2013, 2:73-90

Published Date: 23 July 2013

Allergen immunotherapy: routes, safety,efficacy, and mode of action

Hochfelder JL, Ponda P

ImmunoTargets and Therapy 2013, 2:61-71

Published Date: 23 July 2013

Immunotargeting in the management of psoriasis

Kaffenberger BH, Kaffenberger TM, Wong HK

ImmunoTargets and Therapy 2013, 2:51-60

Published Date: 1 July 2013

Update on the challenges and recent advances in cancer immunotherapy

Baronzio G, Parmar G, Shubina IZH, Cassutti V, Giuli S, Ballerini M, Kiselevsky M

ImmunoTargets and Therapy 2013, 2:39-49

Published Date: 17 June 2013

The association between Lambert–Eaton myasthenic syndrome and small cell lung carcinoma

Briggs SEW, Gozzard P, Talbot DC

ImmunoTargets and Therapy 2013, 2:31-37

Published Date: 22 May 2013

Update on immunopathogenesis and immunotherapy in multiple sclerosis

Selter RC, Hemmer B

ImmunoTargets and Therapy 2013, 2:21-30

Published Date: 26 April 2013

Cancer testis antigen and immunotherapy

Krishnadas DK, Bai F, Lucas KG

ImmunoTargets and Therapy 2013, 2:11-19

Published Date: 18 April 2013

Immunotherapy in the management of melanoma: current status

Alston D, Brewer JD

ImmunoTargets and Therapy 2013, 2:1-10

Published Date: 26 February 2013

T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor- stimulated macrophages

Walk RM, Elliot ST, Blanco FC, Snyder JA, Jacobi AM, Rose SD, Behlke MA, Salem AK, Vukmanovic S, Sandler AD

ImmunoTargets and Therapy 2012, 1:13-23

Published Date: 23 November 2012

Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer

Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S

ImmunoTargets and Therapy 2012, 1:7-12

Published Date: 12 October 2012

Cancer as an immune-mediated disease

Shurin MR

ImmunoTargets and Therapy 2012, 1:1-6

Published Date: 14 June 2012